Changes in Lipid Indices in HIV+ Cases on HAART

Table 1

Clinical information for 63 patients before HAART commencement.

Variables	Mean (±SD) or number (%)
Age (years)	40.47 ± 9.40
Sex
Male	52 (82.5%)
Female	11 (17.5%)
HIV transmission category
Male homosexual	42 (66.7%)
Heterosexual	16 (25.4%)
Unknown	5 (7.9%)
HAART regimen
2 NRTI + PI	14 (22.2%)
2 NRTI + NNRTI	35 (55.6%)
2 NRTI + II	3 (4.8%)
Other	11 (17.5%)
Duration of diagnosis (years)	2.43 ± 3.79
Baseline TC level
Normal	50 (79.4%)
Increased	13 (20.6%)
Baseline TG level
Normal	41 (65.1%)
Increased	22 (34.9%)
Thyroid function
Normal	45 (71.4%)
Abnormal	18 (28.6%)
Sub-hypothyroidism	5 (7.9%)
Overt hypothyroidism	11 (17.5%)
Overt hyperthyroidism	2 (3.2%)
Glucose metabolism
Euglycemia	15 (23.8%)
IFG	34 (54.0%)
DM	14 (22.2%)
HBV or HCV co-infection
neither	48 (76.2%)
HBV	13 (20.6%)
HCV	2 (3.2%)

HIV: human inmunodeficiency virus; HAART: highly active antiretroviral therapy; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; NNRTI: non-nucleoside reverse transcriptase inhibitor; II: integrase inhibitor; TC: total cholesterol; TG: total triglyceride; IFG: impaired fasting glucose; DM: diabetes mellitus; HBV: hepatitis-B virus; HCV: hepatitis-C virus.